Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AnaptysBio, Inc. (ANAB : NSDQ)

• Company Description    AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. Number of Employees: 104

• Price / Volume Information    Yesterday's Closing Price: $67.29 Daily Weekly Monthly 20 Day Moving Average: 498,550 shares Shares Outstanding: 28.75 (millions) Market Capitalization: $1,934.47 (millions) Beta: 0.32 52 Week High: $68.39 52 Week Low: $15.32 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 25.32% 27.69% 12 Week 34.47% 38.35% Year To Date 38.80% 41.47%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10770 WATERIDGE CIRCLE SUITE 210 - SAN DIEGO,CA 92121 USA ph: 858-362-6295 fax: - investors@anaptysbio.com http://www.anaptysbio.com

• General Corporate Information    Officers Daniel Faga - President; Chief Executive Officer and Director Dennis Mulroy - Chief Financial Officer Dennis Fenton - Director Rita Jain - Director Magda Marquet - Director Peer Information AnaptysBio, Inc. (CORR.) AnaptysBio, Inc. (RSPI) AnaptysBio, Inc. (CGXP) AnaptysBio, Inc. (BGEN) AnaptysBio, Inc. (GTBP) AnaptysBio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 032724106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/04/26 Share - Related Items Shares Outstanding: 28.75 Most Recent Split Date: (:1) Beta: 0.32 Market Capitalization: $1,934.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.72 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.04 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 50.07 Price/Cash Flow: - Price / Sales: 8.25 EPS Growth vs. Year Ago Period: 319.44% vs. Previous Quarter: 203.85% Sales Growth vs. Year Ago Period: 151.08% vs. Previous Quarter: 41.84% ROE 12/31/25 - - 09/30/25 - -1,101.24 06/30/25 - -366.98 ROA 12/31/25 - -3.59 09/30/25 - -21.23 06/30/25 - -30.58 Current Ratio 12/31/25 - 9.07 09/30/25 - 8.68 06/30/25 - 8.22 Quick Ratio 12/31/25 - 9.07 09/30/25 - 8.68 06/30/25 - 8.22 Operating Margin 12/31/25 - -5.64 09/30/25 - -49.94 06/30/25 - -107.66 Net Margin 12/31/25 - -5.64 09/30/25 - -49.94 06/30/25 - -107.66 Pre-Tax Margin 12/31/25 - -5.57 09/30/25 - -49.89 06/30/25 - -107.59 Book Value 12/31/25 - 1.34 09/30/25 - -1.06 06/30/25 - -1.52 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - 0.00 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©